| HR (95%CI) | p-value |
---|---|---|
Gender, male/female | 0.761 (0.416–1.393) | 0.377 |
Age, < 66 / ≥66 | 1.171 (0.726–1.887) | 0.517 |
Tumor location: | ||
 UtMt / Lt | 1.076 (0.628–1.845) | 0.789 |
 Ut / MtLt | 0.648 (0.360–1.167) | 0.148 |
Clinical stage: | ||
 cT stage, T1–2 / T3 | 3.543 (2.151–5.838) | < 0.001 |
 cN stage, N0 / N1–2 | 0.301 (0.185–0.488) | < 0.001 |
 cM stage, M0 / M1(LYM) | 0.274 (0.038–1.998) | 0.202 |
PET parameters: | ||
 peakSUVmax, < 4.43 / ≥4.43 | 3.346 (1.929–5.805) | < 0.001 |
 hSULpeak, < 2.64 / ≥2.64 | 3.325 (1.896–5.834) | < 0.001 |
 TMTV, < 3.82 / ≥3.82 | 4.019 (2.313–6.982) | < 0.001 |
 wTLG, < 13.46 / ≥13.46 | 2.996 (1.786–5.024) | < 0.001 |
Pathological stage: | ||
 pT stage, T1–2 / T3–4 | 0.262 (0.162–0.423) | < 0.001 |
 pN stage, N0–1 / N2–3 | 0.211 (0.127–0.350) | < 0.001 |
 pM stage, M0 / M1(LYM) | 0.308 (0.096–0.987) | 0.048 |